Evidence map›Paper›PMID 27303648›Full record

ReviewF1000Research2016

Recent advances in managing and understanding diabetic nephropathy.

Sydney C W Tang, Gary C W Chan, Kar Neng Lai

Registry-linked trialAbstract readReview
In one paragraph

Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03284996 (Role of Doppler Ultrasound in Early Detection of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus.), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03284996 unknown statusnot on this mapstarted 2017, after this paper: background citation

Role of Doppler Ultrasound in Early Detection of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus.

TypeobservationalSponsorAssiut UniversityRan2017 to 2019Enrolled80ConditionsDiabetic NephropathiesArmsDoppler ultrasonography
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Huangqi-Danshen decoction alleviates diabetic nephropathy inAmerican journal of translational research · 2020
    Article
  8. BioMed research international · 2020
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sydney C W TangDivision of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Gary C W ChanDivision of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
Kar Neng LaiDivision of Nephrology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong; Nephrology Department, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy is the commonest cause of end-stage renal disease in most developed economies. Current standard of care for diabetic nephropathy embraces stringent blood pressure control via blockade of the renin-angiotensin-aldosterone system and glycemia control. Recent understanding of the pathophysiology of diabetic nephropathy has led to the development of novel therapeutic options. This review article focuses on available data from landmark studies on the main therapeutic approaches and highlights some novel management strategies.

Indexed as

Diabetic nephropathyglycemia control

Identifiers

PMID27303648
PMCPMC4892357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.